Zanzalintinib Clinical Trials
19 recruitingDrug
Phase 211Phase 18Phase 33
Showing 1–19 of 19 trials
Recruiting
Phase 3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Renal Cell Carcinoma
Merck Sharp & Dohme LLC904 enrolled103 locationsNCT07227402
Recruiting
Phase 3
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC758 enrolled3 locationsNCT07489495
Recruiting
Phase 2
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
Neoadjuvant TreatmentThyroid Cancer
M.D. Anderson Cancer Center45 enrolled1 locationNCT06959511
Recruiting
Phase 2Phase 3
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)
Exelixis440 enrolled80 locationsNCT06943755
Recruiting
Phase 2
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
PembrolizumabPhase 2Zanzalintinib+1 more
M.D. Anderson Cancer Center20 enrolled1 locationNCT07283731
Recruiting
Phase 2
Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis
Locally Advanced Renal Cell Carcinoma
Qian Qin69 enrolled1 locationNCT06794229
Recruiting
Phase 1Phase 2
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Renal Cell Carcinoma
Merck Sharp & Dohme LLC140 enrolled27 locationsNCT07049926
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Renal Cell Carcinoma (RCC)
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 2
A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
Bone Sarcomas
M.D. Anderson Cancer Center70 enrolled1 locationNCT07193550
Recruiting
Phase 2
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma
Metastatic LeiomyosarcomaUnresectable Leiomyosarcoma
Northwestern University29 enrolled1 locationNCT06571734
Recruiting
Phase 1
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
Washington University School of Medicine18 enrolled1 locationNCT06968988
Recruiting
Phase 2
Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)
High Grade Neuroendocrine Neoplasms
Washington University School of Medicine32 enrolled2 locationsNCT06926634
Recruiting
Phase 1
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Endometrial CancerUterine Cancer
Washington University School of Medicine36 enrolled4 locationsNCT06795009
Recruiting
Phase 1
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
Head and Neck NeoplasmsNeoplasm MetastasisCarcinoma, Squamous Cell+3 more
University of Chicago36 enrolled1 locationNCT06912087
Recruiting
Phase 1Phase 2
Maintenance Zanzalintinib With Etoposide After HDCT in GCT
Germ Cell Tumor
Indiana University38 enrolled1 locationNCT06937866
Recruiting
Phase 2
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Hepatocellular Carcinoma
Anwaar Saeed40 enrolled3 locationsNCT06698250
Recruiting
Phase 1
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Advanced LeiomyosarcomaAdipocytic SarcomaAdvanced Liposarcoma
Washington University School of Medicine18 enrolled1 locationNCT06957431
Recruiting
Phase 1
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Moderate Hepatic ImpairmentHepatic Impairment
Exelixis20 enrolled2 locationsNCT06962332
Recruiting
Phase 2
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Stage III Differentiated Thyroid Gland Carcinoma AJCC v8Refractory Differentiated Thyroid Gland CarcinomaLocally Advanced Differentiated Thyroid Gland Carcinoma+18 more
Northwestern University33 enrolled1 locationNCT06959641